Terms: = Prostate cancer AND PWWP2A, Q8IYR3_HUMAN, Q96N64, MST101, MGC132770, KIAA1935, ENSG00000170234, 114825 AND Prognosis
1229 results:
1. Interference with mitochondrial metabolism could serve as a potential therapeutic strategy for advanced prostate cancer.
Wu C; Zhu H; Zhang Y; Ding L; Wang J
PLoS One; 2024; 19(4):e0290753. PubMed ID: 38598542
[TBL] [Abstract] [Full Text] [Related]
2. Factors influencing blood tumor marker concentrations in the absence of neoplasia.
Trapé J; Fernández-Galán E; Auge JM; Carbonell-Prat M; Filella X; Miró-Cañís S; González-Fernández C;
Tumour Biol; 2024; 46(s1):S35-S63. PubMed ID: 38517826
[TBL] [Abstract] [Full Text] [Related]
3. Comparative analysis of prognosis and gene expression in prostate cancer patients with site-specific visceral metastases.
Zhang P; Chen T; Yang M
Urol Oncol; 2024 May; 42(5):160.e1-160.e10. PubMed ID: 38433022
[TBL] [Abstract] [Full Text] [Related]
4. Impact of Tumor Grade Distribution on Genetic Alterations in Clear Cell Renal Cell Carcinoma and prostate cancer.
Mizutani K; Sugiyama S; Kameyama K; Kamei S; Yokoi S; Morikawa A; Takeuchi M; Seike K; Yamada T; Ehara H; Sawada S; Hirade K; Furuta H; Matsunaga K; Yamada T; Sakamoto I; Kato Y; Nishihara H; Ishihara S; Deguchi T
Cancer Genomics Proteomics; 2024; 21(2):203-212. PubMed ID: 38423595
[TBL] [Abstract] [Full Text] [Related]
5. Pan-cancer analysis reveals potential immunological and prognostic roles of METTL7A in human cancers.
Wang B; Jiang J; Luo D; Wang X
Sci Rep; 2024 Feb; 14(1):3476. PubMed ID: 38342956
[TBL] [Abstract] [Full Text] [Related]
6. PRL-mediated STAT5B/ARRB2 pathway promotes the progression of prostate cancer through the activation of MAPK signaling.
Yang T; Chi Y; Wang X; Xu C; Chen X; Liu Y; Huang S; Zhu X; Zhang H; Zhuo H; Wu D
Cell Death Dis; 2024 Feb; 15(2):128. PubMed ID: 38341429
[TBL] [Abstract] [Full Text] [Related]
7. EZH2-mediated development of therapeutic resistance in cancer.
Kaur P; Shankar E; Gupta S
Cancer Lett; 2024 Apr; 586():216706. PubMed ID: 38331087
[TBL] [Abstract] [Full Text] [Related]
8. The sensor applications for prostate and lung cancer biomarkers in terms of electrochemical analysis.
Bounoua N; Cetinkaya A; Piskin E; Kaya SI; Ozkan SA
Anal Bioanal Chem; 2024 Apr; 416(9):2277-2300. PubMed ID: 38279011
[TBL] [Abstract] [Full Text] [Related]
9. Beyond boundaries: unraveling innovative approaches to combat bone-metastatic cancers.
Lan H; Wu B; Jin K; Chen Y
Front Endocrinol (Lausanne); 2023; 14():1260491. PubMed ID: 38260135
[TBL] [Abstract] [Full Text] [Related]
10. Innervation density and types of nerves in prostate cancer.
Blasko F; Krivosikova L; Babal P; Breza J; Trebaticky B; Kuruc R; Mravec B; Janega P
Neoplasma; 2023 Dec; 70(6):787-795. PubMed ID: 38247335
[TBL] [Abstract] [Full Text] [Related]
11. Urological cancers and ChatGPT: Assessing the Quality of Information and Possible Risks for Patients.
Ozgor F; Caglar U; Halis A; Cakir H; Aksu UC; Ayranci A; Sarilar O
Clin Genitourin Cancer; 2024 Apr; 22(2):454-457.e4. PubMed ID: 38246831
[TBL] [Abstract] [Full Text] [Related]
12. Pre-post feasibility trial of a telephone-delivered exercise intervention for patients during chemotherapy for recurrent ovarian cancer: the ECHO-R trial protocol.
Hayes SC; Spence RR; Janda M; Eakin E; Shannon C; Goh J; Beesley VL; Vagenas D; Webb P; Coward J; Gordon LG; O'Neill H; Williams M; Rye S; Newton MJ; Baniahmadi S; Nascimento M; Nicklin J; Garret A; Obermair A
BMJ Open; 2024 Jan; 14(1):e077158. PubMed ID: 38238061
[TBL] [Abstract] [Full Text] [Related]
13. Osteonectin (SPARC) prognostic value in prostate cancer.
Chekhun V; Borikun T; Zadvornyi T; Mushii O; Stakhovsky E; Vitruk Y; Lukianova N
Pathol Res Pract; 2024 Feb; 254():155053. PubMed ID: 38199134
[TBL] [Abstract] [Full Text] [Related]
14. The APE1/REF-1 and the hallmarks of cancer.
Siqueira PB; de Sousa Rodrigues MM; de Amorim ÍSS; da Silva TG; da Silva Oliveira M; Rodrigues JA; de Souza da Fonseca A; Mencalha AL
Mol Biol Rep; 2024 Jan; 51(1):47. PubMed ID: 38165468
[TBL] [Abstract] [Full Text] [Related]
15. A bibliometric perspective with research trends and global productivity on the modernization of andrology from the founder of modern clinical andrology Edward Martin to the present.
Ekici M; Demir E; Aydın C
Eur Rev Med Pharmacol Sci; 2023 Dec; 27(24):11947-11960. PubMed ID: 38164858
[TBL] [Abstract] [Full Text] [Related]
16. Vitamin K: New insights related to senescence and cancer metastasis.
Chen A; Li J; Shen N; Huang H; Hang Q
Biochim Biophys Acta Rev Cancer; 2024 Mar; 1879(2):189057. PubMed ID: 38158025
[TBL] [Abstract] [Full Text] [Related]
17. Experimental validation and pan-cancer analysis identified COL10A1 as a novel oncogene and potential therapeutic target in prostate cancer.
Xu S; Liu D; Qin Z; Liang Z; Xie H; Yi B; Wang K; Lin G; Liu R; Yang K; Xu Y; Zhang H
Aging (Albany NY); 2023 Dec; 15(24):15134-15160. PubMed ID: 38147021
[TBL] [Abstract] [Full Text] [Related]
18. Pathological roles of miRNAs and pseudogene-derived lncRNAs in human cancers, and their comparison as prognosis/diagnosis biomarkers.
Karimi B; Mokhtari K; Rozbahani H; Peymani M; Nabavi N; Entezari M; Rashidi M; Taheriazam A; Ghaedi K; Hashemi M
Pathol Res Pract; 2024 Jan; 253():155014. PubMed ID: 38128189
[TBL] [Abstract] [Full Text] [Related]
19. A novel tumor purity and immune infiltration-related model for predicting distant metastasis-free survival in prostate cancer.
Su Q; Zhu Y; He B; Dai B; Mu W; Tian J
Eur J Med Res; 2023 Nov; 28(1):545. PubMed ID: 38017548
[TBL] [Abstract] [Full Text] [Related]
20. Synergistic effect of docetaxel combined with a novel multi-target inhibitor CUDC-101 on inhibiting human prostate cancer.
Li Z; Quan C; Li W; Ji M
Pathol Res Pract; 2023 Dec; 252():154938. PubMed ID: 37989076
[TBL] [Abstract] [Full Text] [Related]
[Next]
